The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2024-05-11), Prothena's share price is $21.34. Prothena's Book Value per Share for the quarter that ended in Mar. 2024 was $9.35. Hence, Prothena's PB Ratio of today is 2.28.
Good Sign:
Prothena Corp PLC stock PB Ratio (=2.28) is close to 3-year low of 2.23
The historical rank and industry rank for Prothena's PB Ratio or its related term are showing as below:
PRTA'
s PB Ratio Range Over the Past 10 Years
Min: 0.91 Med: 3.37 Max: 12.01
Current: 2.28
During the past 13 years, Prothena's highest PB Ratio was 12.01. The lowest was 0.91. And the median was 3.37.
PRTA's PB Ratio is ranked better than 54.08% of 1311
companies
in the Biotechnology industry
Industry Median: 2.5
vs PRTA: 2.28
During the past 12 months, Prothena's average Book Value Per Share Growth Rate was -18.90% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was 31.40% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was 11.20% per year.
During the past 10 years, the average Book Value Per Share Growth Rate was -0.60% per year.
During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of Prothena was 31.40% per year. The lowest was -24.20% per year. And the median was 8.55% per year.
Back to Basics: PB Ratio
Prothena PB Ratio Historical Data
The historical data trend for Prothena's PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Prothena's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Prothena's PB Ratio Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Prothena's PB Ratio distribution charts can be found below:
* The bar in red indicates where Prothena's PB Ratio falls into.
Prothena PB Ratio Calculation
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
Prothena's PB Ratio for today is calculated as follows:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
Prothena PB Ratio Related Terms
Thank you for viewing the detailed overview of Prothena's PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.
Prothena Corp PLC is a biotechnology company that focuses on protein dysregulation and a pipeline of investigational therapeutics with the potential to change the course of devastating rare neurodegenerative and peripheral amyloid diseases. The company's clinical pipeline of antibody-based product candidates targets a range of indications, including Amyloid Light-chain (AL) amyloidosis (NEOD001), Parkinson's disease and other related synucleinopathies (PRX002), and inflammatory diseases, including psoriasis and psoriatic arthritis (PRX003) and ATTR amyloidosis (PRX004).
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
PRTA has been successfully added to your 